
Chemo-Free Combination of Ribociclib/Trastuzumab/Letrozole Shows PFS Benefit in HR+/HER2+ Breast Cancer
First-line therapy with ribociclib (Kisqali), trastuzumab (Herceptin), and the aromatase inhibitor (AI) letrozole (Femara) with or without a GnRH agonist was effective with a manageable safety profile in patients with metastatic hormone receptor–positive, …